Introduction

I used to think pathology happened somewhere else. In my mind, it belonged to quiet laboratories—spaces of glass slides and fluorescent light where disease was reduced to numbers, stains, and neatly typed reports. Results appeared on screens as if they had always existed that way: objective, self-contained, untouched by the uncertainty of clinical medicine. But while shadowing a GP consultation earlier this year, I watched a single result change not just a diagnosis, but the direction of a conversation.

The patient had not come in with acute symptoms. There was no definitive pathology demanding immediate explanation. Instead, there was a history—fragments of illness across generations, names of relatives spoken with careful distance. Breast cancer in an aunt. Ovarian cancer in a grandmother. Enough to suggest a pattern, but not enough to make it certain. The test itself—a germline *BRCA1/BRCA2* mutation analysis—had been presented cautiously, as a way of clarifying risk rather than confirming disease. It appeared to be simply a blood sample, analysed to detect a mutation already present in every cell. And when the result returned positive, nothing immediate changed. There was no treatment to begin, no procedure to schedule that day.

Yet, the consultation slowed.

The language shifted. What had been a discussion about abstract possibility became a concrete conversation about what comes next.

The Molecular Mechanism & Detection

BRCA1 and *BRCA2* are tumour suppressor genes involved in the high-fidelity repair of double-stranded DNA breaks. Through homologous recombination, they maintain genomic stability by correcting DNA damage before it can accumulate. But when a pathogenic mutation is present, this repair process is compromised; errors persist, and over time, the risk of malignant transformation increases (with lifetime breast cancer risks estimated at 65–80% in *BRCA1* carriers) (*Kuchenbaecker et al., 2017*).

Unlike most pathology tests that capture a moment in time—a spiking C-Reactive Protein flagging acute sepsis, or a blast cell on a peripheral blood smear revealing leukaemia—this result felt different. It did not diagnose active disease; it exposed genomic vulnerability. In the modern laboratory, this isn't caught by a staining rack and a light microscope, but by Next-Generation Sequencing (NGS). As illustrated in Figure 1, genomic DNA is isolated from peripheral blood, sheared, and aligned against a reference genome to pinpoint pathogenic variants like deletions or frameshift mutations (*Kuchenbaecker et al., 2017*).



Figure 1: The Diagnostic Journey of a BRCA Variant

This workflow illustrates the transition from raw biological sample to clinical actionability. By utilizing high-fidelity NGS aligned to the GRCh38 reference genome, the laboratory achieves the depth required for precise variant calling. The final 'Interpretation' stage, guided by ACMG/AMP consensus criteria, is the critical juncture where laboratory data is translated into life-altering clinical management (Plon et al., 2008). Created by the author.

This is where the pathologist's expertise becomes surgical in its precision, filtering through thousands of benign polymorphisms to distinguish a harmless variation from a lethal error.

The Weight of Decision-Making

The true weight of a pathology test is measured by the decisions it demands. For this patient, a positive BRCA result did not trigger immediate treatment, but it did rewrite her clinical horizon. It shifted her from observation into active, pre-emptive management. The conversation in the room pivoted toward risk-reducing surgery—a prophylactic bilateral mastectomy and salpingo-oophorectomy to neutralize the threat before it could manifest (*Domchek et al., 2010*). For a woman in her early thirties, these decisions carry consequences far beyond medicine—affecting her body, her fertility, and her identity. This level of clinical precision gave her agency; instead of waiting for a diagnosis, the pathology report allowed her to intercept it.

Yet, the clarity of a positive result carries its own form of mercy. The inverse—an uninformative or negative genetic report—is often far more complex to navigate. In pathology, a negative result does not always equate to the absence of disease; it may simply reflect the absence of a known explanation. If this patient's test had been negative, her underlying risk would not have disappeared. Instead, it would have remained suspended in diagnostic limbo—a pattern without a name. Clinicians would still be left determining whether her risk was truly baseline or linked to a Variant of Uncertain Significance (VUS) classified under ACMG Class 3 criteria that current databases have yet to define (*Plon et al., 2008*). This is where the interpretive role of the pathologist is most vital. They do not merely report a result; they contextualize it, ensuring that a "negative" result isn't misread as a "clear" bill of health.

Conclusion

It is easy to forget that this single genetic test was just one of 300,000 performed every working day across the United Kingdom. In the rhythm of ward rounds and clinics, laboratory data can feel like background noise—numbers to acknowledge, act on, and move past. But each of those tests represents a precise intersection between a patient's life and a pathologist's interpretation. Whether it is a histology slide identifying the early stages of a melanoma, a HbA1c monitoring the progression of diabetes, or a genetic sequence redefining risk, pathology does not simply support clinical care—it shapes it (*Royal College of Pathologists, 2022*). To treat pathology as a service is to underestimate it; it is not just confirmatory, it is revelatory.

Sitting in that consultation, watching a sequence of nucleotides redraw a woman's life, I realized that pathology is not where a clinical story ends, but where a deeper understanding truly begins. As medical students, we are taught to trust our clinical instincts, but intuition without evidence is fragile. Sometimes, the most important moment in patient care does not happen at the bedside. It happens in the laboratory—where, 300,000 times a day, biology is translated into decisions that shape lives.

References

1. Domchek, S.M. et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA*, 304(9), pp. 967–975.

2. Kuchenbaecker, K.B. et al. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA*, 317(23), pp. 2402–2416.

3. Plon, S.E. et al. (2008). Sequence variant classification and reporting: recommendations for evolving the IARC systems. *Human Mutation*, 29(11), pp. 1282–1291.

4. Royal College of Pathologists. (2022). *The pathology workforce: delivering diagnostic services for patients*. [Online]. London: RCPath. Available at: https://www.rcpath.org [Accessed 20 March 2026].